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Abstract 
 
Objective: Soluble mediators in synovial fluid are acknowledged as key players in the 
pathophysiology of osteoarthritis (OA). However, a wide-spectrum screening of such 
mediators in synovial fluid is currently lacking. In this study, the levels of 47 mediators in the 
synovial fluid of control donors and osteoarthritic (OA) patients were compared. 
Materials & Methods: Synovial fluid was collected from control donors (n=16) and end-
stage knee OA patients (n=18) and analysed for 47 cytokines, chemokines and growth factors 
using several multiplex ELISAs. A Mann-Whitney U test was used to determine differences 
between OA and control controls. A principal component analysis (PCA) was performed to 
cluster the 47 mediators. 
Results: The majority of the mediators could be detected in both control and OA synovial 
fluid. IL-6, IP-10, MDC, PDGF-AA and RANTES levels were found to be higher in OA 
compared to control synovial fluid (p<0.001). Leptin, IL-13, MIP-1β, sCD40L levels were 
higher and eotaxin and G-CSF levels were lower in OA synovial fluid than in control synovial 
fluid, albeit borderline significant (p<0.05). The PCA enabled identification of 6 clusters of 
mediators, which explained 76% of the variance.   
Conclusions: The current study provides the first extensive profile of cytokines, chemokines 
and growth factors present in control and OA synovial fluid. Increased levels of mediators 
such as MDC and IL-6 imply involvement of inflammatory processes and might be associated 
with the influx of inflammatory cells in OA synovial tissue. Moreover, the performed cluster 
analysis indicated multiple clusters, which could indicate different pathophysiological 
pathways in the joint. 
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 1 
Summary 1 
 2 
Soluble mediators, e.g. cytokines, chemokines and growth factors, are acknowledged as key 3 
players in the pathophysiology of osteoarthritis (OA) (1, 2). However, a wide-spectrum 4 
screening of such mediators in the joint environment is currently lacking. In this study, 5 
synovial fluid was collected from control donors and end-stage knee OA patients and 6 
analysed for 47 cytokines, chemokines and growth factors using several multiplex ELISAs. 7 
In addition, a principal component analysis (PCA) was performed to cluster the measured 8 
mediators. IL-6, IP-10, MDC, PDGF-AA and RANTES levels were found to be higher in OA 9 
compared to control synovial fluid (p<0.001). Leptin, IL-13, MIP-1β, sCD40L levels were 10 
higher and eotaxin and G-CSF levels were lower in OA synovial fluid than in control 11 
synovial fluid, albeit at borderline significance (p<0.05). Increased levels of inflammatory 12 
mediators and chemokines, such as MDC and IL-6, imply involvement of inflammatory 13 
processes in OA and might be associated with the influx of inflammatory cells in OA 14 
synovial tissue. Additionally, the PCA enabled identification of 6 different clusters, which 15 
explained 76% of the variance, and in this way could indicate different pathophysiological 16 
pathways in the joint. This dataset is valuable as a reference for future experiments to study 17 
pathophysiological pathways, and useful in more extensive profiling studies for OA. 18 
 19 
Brief report 20 
 21 
A control group of knee synovial fluid samples (n=16) were collected from post 22 
mortem donors within 24 hours after death. Control donors had no history of OA, other joint 23 
pathology and possessed macroscopic healthy cartilage. OA synovial fluid samples (n=18) 24 
were collected during total knee arthroplasty. All OA patients were diagnosed according to 25 
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 2 
the ACR criteria for OA (3). Exclusion criteria were rheumatoid arthritis (RA) or infection. 26 
Synovial fluid samples were centrifuged at 3000 rpm for 3 minutes to spin down any cells or 27 
debris. The supernatant was stored at -80 °C until further analysis. The control synovial fluid 28 
samples were stored for 1 to 10 years and OA synovial fluid samples were stored for 1 to 3 29 
years. None of the samples had ever been thawed before. Collection of the synovial fluid was 30 
done according to the Medical Ethical regulations of the University Medical Centre Utrecht 31 
and according to the guideline ‘good use of redundant tissue for clinical research’ constructed 32 
by the Dutch Federation of Medical Research Societies on collection of redundant tissue for 33 
research. As according to these guidelines, no information about the patients’ characteristics 34 
could be obtained. Gender and age information was available for limited donors. Control 35 
donors had an average age of 39.6 ± 9.3 and consisted of 55% female. OA donors had an 36 
average age of 69.9 ± 7.9 and consisted of 64 % female. Due to the limited availability these 37 
data could not be linked to any of the outcomes.  38 
Two hundred µl of each of the OA synovial fluid samples was pre-treated with 20 µl 39 
of hyaluronidase (Sigma, St, Louis, MO, USA; 10 mg/ml) for 15 min at 37 °C. Samples were 40 
spun down in a X-column (Corning, Amsterdam, Netherlands; Costar 8169). Finally, 150 µl 41 
of the synovial fluid sample was dissolved in 300 µl HPE-0.1375% Tween (Sanquin, 42 
Amsterdam, Netherlands). The pre-treated synovial fluid samples were used for all Multiplex 43 
ELISA assays mentioned below. 44 
To determine a wide panel of soluble mediators the commercially available human 45 
inflammation 42-multiplex and the human adipokine 13-multiplex (Millipore, Bellirica, MA, 46 
USA) were used according to the manufacturer’s protocol. Additionally, 12 different soluble 47 
mediators were measured with the Bio-Plex suspension system (Bio-Rad laboratories, 48 
Hercules CA, USA) as previously described (4). The levels of cytokines in the synovial fluid 49 
samples were expressed as pg/ml. All samples were measured in the same plate and in duplo. 50 
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 3 
Levels below the lower limit of quantification (LLOQ) were indicated as the value of the 51 
lowest point on the calibration curve divided by 2. The measured mediators are listed in table 52 
1. Data are expressed as median ± interquartile range (IqR) as the data had a non-Gaussian 53 
distribution. IBM SPSS 20.0 software (IBM SPSS Inc. Chicago, IL, USA) was used for the 54 
statistical analysis.  55 
For this study, a descriptive statistics approach was used for the interpretation of the 56 
data due to the limited sample size. A Mann Whitney-U test was used to assess differences 57 
between control and OA synovial fluid samples due to the predominantly non-Gaussian 58 
distribution of the data. As a descriptive statistic approach was used, values with a p-value 59 
less than 0.001 were considered significant. P values between 0.05 and 0.001 were 60 
considered borderline significant. No post-hoc correction for multiple testing was performed 61 
on the data, due to the descriptive approach. 62 
PCA was performed to enable identification of clusters (i.e. components) of 63 
interrelated mediators within the complete dataset. Mediator levels were mean-centered to 64 
remove dependence on magnitude of levels. Control and OA patient data were combined in 65 
one single PCA analysis. Separate analysis of patients and controls was judged impossible 66 
due to the limited number of subjects. Only mediators with communalities > 0.3 were 67 
included. Loading factors were maximized using Direct oblimin rotation with Kaiser 68 
Normalisation. The optimum number of clusters was then decided based on the scree-plot 69 
and eigenvalues (> 1.0). Mediators were categorized per cluster when their loading scores 70 
were > 0.5. A Crohnbach’s α was performed on each cluster to determine internal 71 
consistency.  72 
 This is one of the first studies in which such a comprehensive profile of soluble 73 
mediators was measured in synovial fluid from (end-stage) OA patients and control donors. 74 
With regard to previous studies, the pattern of the mediator levels was found to be compatible 75 
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 4 
for OA donors. However, in these studies a small panel of mediators was measured and the 76 
inclusion of  control donors was lacking (e.g. (5)). Table 1 provides an overview of the 77 
measured levels of each mediator (median ± IqR). The majority of the soluble mediators 78 
could be detected in the synovial fluid samples of both control and OA donors. Of the 47 79 
measured mediators, 5 mediators were present at significantly different levels in OA 80 
compared to control synovial fluid. The levels of the chemokines MDC, RANTES and IP-10, 81 
the growth factor PDGF-AA and the pro-inflammatory cytokine IL-6 were significantly 82 
higher in OA than in control synovial fluid (p < 0.001). In addition, levels of the adipokine 83 
leptin, the chemokine MIP-1β, and the pro-inflammatory cytokine sCD40L were higher and 84 
levels of the chemokine eotaxin and the growth factor G-CSF were lower in OA than in 85 
control synovial fluid, albeit all with borderline significance (p < 0.05).  86 
The PCA was performed to gain insight into the associations between individual 87 
mediators that were assessed. The PCA showed communalities > 0.3, which as such, were 88 
included in the analysis. PCA enabled identification of 6 clusters of interrelated mediators 89 
among the spectrum of 47 mediators (Table 2). These clusters may reflect important 90 
pathophysiological pathways in the joint. In the pattern matrix, the mediators IFNγ, OSM, IL-91 
7, IL-1β, IL-8 and TGFα were clustered in the first cluster, and together explained 30.2 % of 92 
the total variance with an eigenvalue of 10.5. Cluster 2 included IL-3, MIP-1α, EGF, leptin 93 
and IL-12, (variance explained 16.8%, eigenvalue 5.9). Cluster 3, contained MCP-1, IL-10, 94 
eotaxin and G-CSF (variance explained 10.8%; eigenvalue 3.8). Cluster 4 contained 95 
RANTES, PDGF-AB/BB, PDGF-AA, sCD40L, IP-10, IFNα (variance explained 6.4%, 96 
eigenvalue 2.2). Cluster 5 included Flt-3 ligand, HGF, IL-15 and sIL-2ra (variance explained 97 
6.1%, eigenvalue 2.1). Cluster 6 included the adipokines IL-6 and resistin (variance 98 
explained 6.0%, eigenvalue 2.1). In total, these 6 clusters explained more than 76% of the 99 
variance. The first two clusters mainly contained pro-inflammatory mediators and cluster 3 100 
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 5 
included predominantly chemokines. Cluster 4 contained predominantly growth factors and 101 
cluster 5 factors associated with T-cell proliferation and maturation. Finally, cluster 6 102 
contained only adipokines. Mediators in all these 6 clusters are known to be part of important 103 
processes in the joint homeostasis. However, distinguishing between potential clusters was 104 
difficult, since these mediators are involved in adjacent and interrelated pathways.  105 
Cytokines, chemokines, adipokines and growth factors play a major role in 106 
inflammatory diseases, such as OA, and are currently intensively studied. The adipokines are 107 
associated with obesity, which is in itself associated with low-grade systemic inflammation, 108 
one of the risk factors for the development and progression of OA (2, 6, 7). The different 109 
levels of IL-6, leptin and adiponectin between control and OA synovial fluid might indicate a 110 
role for certain adipokines in OA processes, which is in line with literature (7). However, 111 
these data were not corrected for BMI, which might influence the outcomes. Another group 112 
of mediators consisted of chemokines. The measured chemokines such as the related 113 
Chemokines-Chemokines (CC) mediators RANTES, MDC, MIP-1α and MIP-1β were higher 114 
in OA than in control synovial fluid. This group of chemokines share the same receptor 115 
complexes, e.g. CCR1, CCR2 and CCR5 (8) and their major function is to attract 116 
inflammatory cells, e.g. T-cells, macrophages and other inflammatory cells to sites of 117 
inflammation. Chemokines, such as RANTES, are also capable of activating (inflammatory) 118 
cells in the production of inflammatory mediators. As shown in previous studies, RANTES 119 
promotes the production of IL-6 by synovial fibroblasts and enhances the inflammatory 120 
response in OA through the different CCR receptor in synovial tissue (9). Moreover, CCR 121 
receptors are present in chondrocytes and treatment of cartilage explants with RANTES was 122 
demonstrated to increase release of proteoglycans (10). The combination of multiple CC-123 
chemokines in combination with IL-6 and leptin in the synovial fluid was not demonstrated 124 
earlier. Blocking these CC-chemokines or their receptors in OA might reduce IL-6 and leptin 125 
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 6 
production and, consequently, the infiltration of inflammatory cells and the production of 126 
catabolic factors in the joint. Future research is necessary to elucidate this.  127 
In none of the synovial fluid samples GM-CSF, IL-12(p70), IL-13, IL-17, IL-2, IL-4, 128 
IL-5, IL-7, IL-9, TNFβ, VEGF and NGF and TNFα, could be detected. IL-1 was only 129 
detected at very low levels. TNFα and IL-1 are pro-inflammatory cytokines, which are 130 
associated with cartilage degeneration, synovial inflammation and bone changes (11). 131 
Although in some in vivo animal models of OA, blocking IL-1 or TNFα gave promising 132 
results, this could not be validated in clinical studies (12). Our results likewise do not support 133 
a prominent role for IL-1 and TNFα in end-stage OA patients. Nonetheless, this does not 134 
exclude a role for IL-1 and TNFα in for example early OA, as OA has a heterogeneous 135 
character with multiple phenotypes.  136 
For the interpretation of the data it should be mentioned that our results are based on a 137 
small sample size, due to donor availability, which were not paired on age, BMI and sex. 138 
Moreover, it should be taken into account that ex-vivo modifications cannot be excluded for 139 
the control donors as samples were taken after death. Also due to the small sample size, no 140 
further statistics were performed on the PCA to study differences between the clusters for OA 141 
and control synovial fluid samples. Therefore this pilot dataset should be regarded as a 142 
reference and more extensive profiling studies are necessary to confirm these data. 143 
In summary, this is the first study measuring a wide panel of mediators in the synovial 144 
fluid of both control and end-stage OA donors. Increased levels of mediators such as MDC, 145 
IL-6 and RANTES once more confirm involvement of inflammatory processes and might be 146 
associated with the influx of inflammatory cells in OA synovial tissue. In addition, the PCA 147 
indicated 6 clusters, which reflect different processes in the joint. Due to the small samples 148 
size no hard conclusions can be drawn. Nonetheless, this pilot dataset provides a valuable 149 
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 7 
reference for future experiments to study pathophysiological pathways, and to be useful in 150 
more extensive profiling studies for OA.  151 
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Table 1: Overview of the measured mediator concentration (pg/ml) in control and 
osteoarthritic (OA) synovial fluid (SF). Data are indicated as median ± Interquartile Range 
(IqR). The coefficient of variation (CV) in percentage and Lower Limited of Quantification 
(LLOQ) with the number of samples are given. Data are subjected to non-parametric 
statistical analysis Mann-Whitney U; *p<0.05 and # p<0.001. GM-CSF, IL-12(p70), IL-13, 
IL-17, IL-2, IL-4, IL-5, IL-7, IL-9, TNFα, TNFβ, VEGF and NGF could not be detected. 
  Healthy 
SF 
(Median 
± IqR)  
CV 
(%) 
<LLOQ 
or 0 (n) 
OA SF 
(Median 
± IqR) 
CV 
(%) 
<LLOQ 
or 0 (n) 
Detection 
limit 
Mann-
Whitney 
U (p-
value) 
EGF  4.8 ± 
13.1 
102.3 11 4.8 ± 0 189.3 14 5.3 0.65 
Eotaxin  14.6 ± 
39.6 
96.0 6 0 ± 0 236.7 15 12.1 *0.02 
FGF-2  37.2 ± 
70.4 
137.5 2 21.6 ± 
231.4 
134.1 4 16.0 0.67 
Flt-3 ligand  135.9 ± 
119.7 
59.0 0 103.5 ± 
76.4 
53.1 0 6.1 0.23 
Fractalkine  0 ± 0 387.7 14 0 ± 19 168.5 12 7.6 0.14 
G-CSF  34.8 ± 
151 
105.9 1 16.9 ± 
15 
66.9 0 3.9 *0.03 
GRO  59.2 ± 
79.5 
74.4 0 84.2 ± 
96 
81.6 0 11.4 0.38 
IFNα2  7.2 ± 
10.5 
67.4 7 16.4 ± 
46.8 
89.3 7 27.2 0.09 
IFNγ  40.7 ± 
12.9 
23.30 0 28.0 ± 
21.0 
136.74 2 2.14 0.1 
IL-10  3.3 ± 6.3 127.6 6 2.1 ± 2.7 103.7 3 0.3 *0.04 
IL-12 (p40)  4.8 ± 1.7 60.5 9 4.8 ± 
11.9 
137.7 10 12.4 0.30 
IL-15  9.9 ± 6.0 37.1 0 12.8 ± 
5.7 
31.2 0 0.6 0.32 
IL-1α  0 ± 1.8 217.8 9 0 ± 4.9 153.4 12 1.5 0.74 
IL-1ra  0 ± 6.9 125.6 8 0 ± 0 288.4 14 2.3 0.14 
IL-1ß  0 ± 1.5 205.4 11 4.8 ± 
11.9 
298.6 14 0.7 0.61 
IL-3  0 ± 0 0.0 16 4.8 ± 0 179.3 16 9.8 0.18 
IL-6  4.8 ± 0 196.9 13 135.8 ± 
224.6 
120.3 3 0.4 #0.001 
IL-8  16.2 ± 
43.5 
92.2 0 30 ± 
23.5 
170.9 0 0.3 0.24 
IP-10  302.1 ± 
280.8 
107.6 0 710.4 ± 
597.1 
93.1 0 1.3 #0.001 
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MCP-1  542.4 ± 
839.2 
102.1 0 824.8 ± 
645.5 
47.8 0 1.2 0.58 
MCP-3  4.8 ± 36 123.5 10 4.8 ± 5 215.5 14 5.2 0.83 
MDC  52.2 ± 
38.4 
43.9 0 189.5 ± 
119.8 
41.8 0 2.4 #0.001 
MIP-1α  4.8 ± 0 26.7 16 4.8 ± 0 172.7 15 6.6 0.06 
MIP-1ß  9.6 ± 
24.0 
83.7 5 21.8 ± 
23.5 
127.6 3 3.2 *0.04 
PDGF-AA  0 ± 2.1 201.3 11 72.6 ± 
116.9 
72.8 0 0.3 #0.001 
PDGF-
AB/BB 
 43.2 ± 
42.9 
93.6 1 34.2 ± 
69.7 
137.8 0 12.2 0.44 
RANTES  15.6 ± 
28.1 
152.7 0 408.2 ± 
910.9 
114.3 0 1.6 #0.001 
sCD40L  0 ± 0 230.9 13 5.9 ± 
45.1 
144.6 7 5.2 *0.005 
sIL-2ra  37.5 ± 
76.8 
90.8 1 63.0 ± 
72.5 
65.9 0 7.5 0.11 
TGFα  0 ± 0.6 201.2 9 0 ± 0 401.5 17 1.4 0.4 
HGF  2554.4 ± 
3505.7 
80.2 0 2303 ± 
1695.2 
38.12 
 
0 1.6 0.32 
Leptin  82.2 ± 
1565.3 
133.21 
 
4 1637.5 ± 
2414.1 
125.33 
 
0 27.4 *0.01 
Resistin  2713.4 ± 
1854.6   
87.25 
 
0 3824.8 ± 
3550.7 
72.71 
 
0 4.5 0.12 
Adiponectin  >250000 na na >250000 na na 80.3 na 
OSM   0 ± 0 447.83 
 
16 0 ± 0 307.79 
 
12 1.59 0.09 
          
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2. Pattern matrix after Oblimin rotation with Kaiser Normalisation as obtained from 
PCA in the spectrum of synovial fluid mediators. Control and osteoarthritic samples were 
combined. Only loading factors > 0.5 are displayed.  
Action Mediator   Cluster    
  1 2 3 4 5 6 
Pro-inflammatory IFNγ 0.988      
Pro-inflammatory OSM 0.980      
Pro-inflammatory IL-7 0.971      
Pro-inflammatory IL-1β 0.947      
Anti-inflammatory IL-1ra 0.851      
Chemokine MCP-3 0.849      
Pro-inflammatory IL-8 0.823      
Growth factor TGFα 0.612      
Pro-inflammatory IL-3  0.942     
Chemokine MIP-1α  0.919     
Proliferation EGF  0.888     
Adipokine Leptin  0.871     
Proliferation IL-12  0.702     
Chemokine MCP-1   0.841    
Anti-inflammatory IL-10   0.807    
Chemokine Eotaxin   0.653    
Chemokine G-CSF   0.622    
Chemokine RANTES    -0.953   
Growth factor PDGF-AB/BB    -0.935   
Growth factor PDGF-AA    -0.914   
Chemokine IP-10    -0.705   
Growth factor sCD40L    -0.683   
Pro-inflammatory IFNα    -0.589   
T-cell factor Flt-3 ligand     -0.827  
Growth factor HGF     -0.795  
T-cell factor IL-15     -0.703  
T-cell factor sIL-2ra     -0.565  
Adipokine IL-6      0.922 
Adipokine Resistin      0.678 
Eigenvalues  10.5 5.8 3.8 2.2 2.1 2.1 
Variances explained (%)  30% 17% 11% 6% 6% 6% 
Cronbach’s alphas  0.835 0.059 0.114 0.615 0.070 0.115 
        
 
